These emerging treatments, Semaglutide , represent a significant advancement in managing metabolic dysfunction and conceivably other disorders. They are classified as GLP-1 hormone agonists , meaning they function to emulate the endogenous GLP-1 substance , boosting metabolic release and suppressing hunger . While Tirzepatide each functions largely